FierceBiotechOriginal article
{"a":[{"_":"Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors","$":{"href":"/biotech/q32s-stock-jumps-60-latest-phase-2-alopecia-data-complement-inhibitor","hreflang":"en"}}]}
Phase 2positivePositive
AI Analysis
Summary
Q32 Bio's Phase 2 alopecia candidate demonstrated positive results, causing the company's stock to jump 60%. The data supports the potential for the complement inhibitor to offer a more durable alternative to JAK inhibitors.
Clinical Trial Data
Phase
2
Outcome Details
Phase 2 data showed positive results, with investors responding positively to the data readout
Importance:7/10
Sentiment:
0.85
Phase 2alopeciaJAK inhibitorcomplement inhibitorstock increase
Related Companies
Read the original article
Published by FierceBiotech on July 13, 2026 9:59 AM